Scotland is expanding drug-checking centres and introducing point-of-care testing to tackle contaminated drugs in a rapidly changing illicit market. This page breaks down what’s happening, how access could change, what critics are warning about, and what evidence supports harm reduction through drug checking. Explore common questions and clear answers to understand the broader harm-reduction landscape.
Scotland is expanding drug-checking capacity in response to rising drug contamination and evolving threats in the illicit market. A national lab will be hosted in Dundee, with additional point-of-care testing licences in Glasgow, Aberdeen and Dundee, while Edinburgh awaits Home Office approval. The move aims to curb harms by providing timely information about what’s in drugs before they’re used.
The plan includes three new drug-checking centres and a national lab in Dundee, plus point-of-care testing licences in Glasgow, Aberdeen and Dundee. This setup allows faster analysis of samples and wider access for users, with ongoing debates about eligibility rules and what counts as a ‘dependent’ for access.
Point-of-care testing is designed to speed up results so users can quickly know what’s in their drugs. This should improve access by reducing wait times and enabling services to operate closer to communities. However, access rules and the undefined term 'dependent' raise questions about who can use these services and how broadly harm-reduction benefits can reach.
Critics are highlighting uncertainties around regulatory limits, eligibility, and who may access services. With Edinburgh awaiting Home Office approval, there are concerns about consistency, safety, and potential barriers for some users. Defining terms like 'dependent' and setting clear age or eligibility rules are also part of the ongoing debate.
Experts argue that drug checking can reduce harm by identifying dangerous adulterants and enabling timely risk warnings. The approach relies on rapid, accurate testing and broad access to information. While international coverage shows growing interest in harm-reduction tools, local implementation depends on regulatory clarity, funding, and genuine accessibility for diverse user groups.
Success would involve faster, wider access to reliable drug-testing results, clearer eligibility rules, and measurable reductions in harm (such as fewer overdoses related to contaminated substances). Ongoing evaluation and transparent reporting will be key to demonstrating impact and guiding future policy decisions.
In a letter to states and other grant recipients, the Trump administration says the strips encourage drug use.